TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›MGRX›Financials
Annual statements · SEC XBRL · FY2022 – FY2025

MANGOCEUTICALS, INC. (MGRX) financials

Income statement

MANGOCEUTICALS, INC. (MGRX) income statement, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Revenue$8.94K$731K$616K$456K
Revenue growth—8083.2%-15.8%-26.0%
Gross profit$4.85K$432K$380K$250K
Gross margin54.3%59.0%61.7%54.9%
Operating income-$1.99M-$9.22M-$7.97M-$18.0M
Operating margin-22279.7%-1260.3%-1294.4%-3954.3%
Net income-$2.00M-$9.21M-$8.71M-$20.6M
Net margin-22352.1%-1259.4%-1413.6%-4526.8%
EPS (diluted)-$0.19-$8.58-$4.80-$2.17

Cash flow

MANGOCEUTICALS, INC. (MGRX) cash flow, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Operating cash flow-$1.35M-$7.00M-$4.86M-$5.85M
Capital expenditures$43.1K$3.52K——
Free cash flow-$1.39M-$7.00M——

Balance sheet

MANGOCEUTICALS, INC. (MGRX) balance sheet, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Cash & equivalents$683K$739K$58.7K$1.49M
Total assets$1.00M$1.05M$15.4M$16.1M
Total liabilities$389K$276K$1.43M$891K
Shareholders' equity$614K$775K$13.9M$15.2M
Retained earnings-$2.02M-$11.2M-$20.0M-$40.6M
Shares (wtd avg diluted)10.8M1.07M1.98M10.1M

Every figure is extracted from MANGOCEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is MANGOCEUTICALS, INC.'s annual revenue?
MANGOCEUTICALS, INC. (MGRX) reported $456K of revenue for fiscal year 2025 — down 26.0% from $616K in FY2024, per its annual report filed with the SEC.
Is MANGOCEUTICALS, INC. profitable?
Not in FY2025 — MGRX reported a net loss of $20.6M, per SEC filings.
Does MGRX pay a dividend?
MANGOCEUTICALS, INC. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full MGRX analysis — verdict, score & filings →Is MGRX a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.